<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03877484</url>
  </required_header>
  <id_info>
    <org_study_id>ALLEV.PMCF.2017.13</org_study_id>
    <nct_id>NCT03877484</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Effectiveness of ALLEVYN Gentle Border</brief_title>
  <official_title>A Prospective, Multi-center, Post-Market Clinical Follow-Up Study to Evaluate the Safety and Effectiveness of ALLEVYN Gentle Border</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith &amp; Nephew Orthopaedics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smith &amp; Nephew, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical study will evaluate the safety and effectiveness of the ALLEVYN Gentle Border.&#xD;
      The study is a post-market clinical follow-up to assess clinical performance and safety of&#xD;
      ALLEVYN Gentle Border with new wound contact layer to support performance claims.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical performance as measured by change in size of the wound area (cm2) over 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in wound area from baseline to days 7, 14 and 21</measure>
    <time_frame>up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in wound depth (mm) from baseline to days 7, 14, 21 and 28</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in wound area from baseline to days 7, 14, 21 and 28</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of wound dressing performance measures at days 7, 14, 21 and 28</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Description: Clinical and Dressing performance endpoints include: exudate type, amount and viscosity, odour control, dressing change frequency, condition of surrounding skin, signs of clinical infection, healing of reference wound, dressing wear time, dressing retention, presence of bunching up, percentage dressing lift, comfort during wear, showerproof qualities and pain on application, during treatment and on dressing removal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subject reported outcomes using the Cardiff Wound Impact Schedule</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse Events and Device Deficiencies</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in wound volume (cm3) from baseline to days 7, 14, 21 and 28</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in wound depth from baseline to days 7, 14, 21 and 28</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in wound volume from baseline to days 7, 14, 21 and 28</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Wound</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ALLEVYN Gentle border</intervention_name>
    <description>ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Forty adult subjects with moderate to highly exuding wounds that require a dressing will be&#xD;
        recruited. Only subjects with acute wounds or chronic wounds which are present &gt; 6 weeks&#xD;
        will be enrolled. Chronic wounds will include pressure ulcers, leg ulcers, diabetic foot&#xD;
        ulcers. Acute wounds will include dehisced surgical or traumatic wounds. In order to ensure&#xD;
        a balanced distribution on chronic and acute indications, at least 10 subjects with chronic&#xD;
        wounds and at least 10 subjects with acute wounds will be enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent.&#xD;
&#xD;
          2. 18 years of age or older.&#xD;
&#xD;
          3. Willing and able to make all required study visits.&#xD;
&#xD;
          4. Able to follow instructions and deemed capable of completing the CWIS questionnaire,&#xD;
             Patient Assessment Scale and Pain Scale.&#xD;
&#xD;
          5. Presence of a moderately to highly exuding wound of at least 3cm2 in size.&#xD;
&#xD;
          6. Presence of a chronic wound of at least 6 weeks duration at the point of enrollment;&#xD;
             full-thickness, partial thickness or shallow granulating wounds.&#xD;
&#xD;
             Chronic wounds include:&#xD;
&#xD;
               -  pressure ulcers or&#xD;
&#xD;
               -  leg ulcers or&#xD;
&#xD;
               -  diabetic foot ulcers&#xD;
&#xD;
             or&#xD;
&#xD;
             Presence of an acute wound at the point of enrollment; full thickness, partial&#xD;
             thickness or shallow granulating wounds&#xD;
&#xD;
             Acute wounds include:&#xD;
&#xD;
               -  dehisced surgical or&#xD;
&#xD;
               -  traumatic wounds&#xD;
&#xD;
          7. The patient has a wound size which can be treated with the available sizes and shapes&#xD;
             of ALLEVYN Gentle Border. Cutting of the dressing is allowed, if needed. ALLEVYN&#xD;
             Gentle Border can be cut and an aseptic technique should be used with cutting the&#xD;
             dressing. Ensure any exposed foam areas are covered with an appropriate film dressing&#xD;
             taking care not to cover the entire dressing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with confirmed or suspected clinically infected reference wound.&#xD;
&#xD;
          2. Reference wound undergoing treatment with compression therapy.&#xD;
&#xD;
          3. Contraindications or hypersensitivity to the use of the ALLEVYN Gentle Border.&#xD;
&#xD;
          4. Participation in the treatment period of another clinical trial within 30 days of&#xD;
             Visit 1 or planned participation overlapping with this study.&#xD;
&#xD;
          5. Subjects with skin features (e.g. tattoos, skin color, pre-existing scarring) which,&#xD;
             in the opinion of the Investigator, could interfere with the study assessments.&#xD;
&#xD;
          6. Subjects who have participated previously in this clinical trial.&#xD;
&#xD;
          7. Subjects with a history of poor compliance with medical treatment.&#xD;
&#xD;
          8. Subjects with a medical or physical condition that, in the opinion of the&#xD;
             Investigator, would preclude safe subject participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Reinhold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VZ Dermatologisches Zentrum Bonn</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cornelia Erfurt-Berge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Erlangen, Department of Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrike Raap, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Oldenburg, Universitätsklinik für Dermatologie und Allergologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judith Horner</last_name>
    <phone>+44 (0) 1482 673251</phone>
    <email>judith.horner@smith-nephew.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachael Winter</last_name>
    <phone>+44 (0) 1482 673475</phone>
    <email>rachael.winter@smith-nephew.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier William Morey</name>
      <address>
        <city>Chalon-sur-Saône</city>
        <zip>71321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>MVZ Dermatologisches Zentrum Bonn GmbH</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Erlangen, Department of Dermatology</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Niels-Stensen-Kliniken Christliches Klinikum Melle GmbH</name>
      <address>
        <city>Melle</city>
        <zip>49324</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg, University Clinic for Dermatology and Allergy</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Northumbria Healthcare NHS Foundation Trust</name>
      <address>
        <city>Ashington</city>
        <state>Northumberland</state>
        <zip>NE63 0HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Jones</last_name>
      <email>louise.jones@northumbria-healthcare.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jeanette Milne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid-Yorkshire Hospitals NHS Trust</name>
      <address>
        <city>Wakefield</city>
        <zip>WF1 4DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Sylvester</last_name>
      <email>Martin.Sylvester@midyorks.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Leanne Atkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic and acute wounds</keyword>
  <keyword>full-thickness</keyword>
  <keyword>partial thickness</keyword>
  <keyword>shadow granulating</keyword>
  <keyword>exuding wounds</keyword>
  <keyword>including pressure ulcers</keyword>
  <keyword>leg ulcers</keyword>
  <keyword>diabetic foot ulcers</keyword>
  <keyword>dehisced surgical wounds</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

